NASDAQ
24.44USD
-2.48 (-9.21%)
We have scored 4 news catalysts on Parabilis Medicines, Inc. (PBLS) over the past 12 months. The biggest single-day move next to one of them came Jun 10, 2026, when PBLS closed +58.0%: “Parabilis Medicines Announces Pricing of Upsized Initial Public Offering”. Coverage across the window leans positive (average ticker sentiment +0.78). Most of the impact sits in sector healthcare and price momentum.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
3B
P/E
—
EPS
—
Beta
5.03
52W range
20-42.49
Day range
23.96–26.74
Open
26.74
Prev close
26.92
Volume
1.8M
Avg volume
758.1K
Dividend
0.00
IPO
2026-06-10
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Parabilis Medicines, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for PBLS: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Fog Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane in 2015 and is headquartered in Cambridge, MA.
